258886-04-3Relevant articles and documents
INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION
-
Paragraph 1663-1664, (2020/03/01)
Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.
SGLTS INHIBITOR AND APPLICATION THEREOF
-
Paragraph 0117-0120, (2020/11/30)
A compound as an SGLT1/SGLT2 dual inhibitor, and an application thereof in the preparation of a drug as the SGLT1/SGLT2 dual inhibitor. The compound is a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof
Method for preparing alcoholic compound from anilino lithium compound as catalyst
-
Paragraph 0030, (2019/03/06)
The invention relates to an application of an anilino lithium compound, in particular to a method for preparing an alcoholic compound from the anilino lithium compound as a catalyst. The catalyst, borane and carboxylic acid are stirred and mixed uniformly, subjected to a reaction and exposed to air to terminate the reaction, a reacted liquid is subjected to reduced-pressure treatment for solvent removal, silica gel and methanol are added, and the alcoholic compound is obtained by hydrolysis. The anilino lithium compound can perform high-activity catalysis on the reaction between carboxylic acid and borane at room temperature, dose of the catalyst is only 0.8mol% of the mole ratio of carboxylic acid, compared with the conventional catalysis system, the commercial reagent anilino lithium compound is used, reaction conditions are mild, and yield of borate with different substituents under limit conditions can reach 90% or higher.